Core Insights - Guizhou BaiLing conducted an institutional research meeting on November 12, 2025, attracting 15 institutions and several individual investors to discuss core product development, supply chain management, market expansion, and financial status [1] Product Development Progress - The focus of the research was on the development of two core products: Tang Ning Tong Luo and Huang Lian Jie Du Wan. Tang Ning Tong Luo has received approval for its first indication, diabetic retinopathy, and has entered phase III clinical trials with 360 patients being enrolled. The company plans to submit a market application after completing the trials. Additionally, the drug has received a clinical trial approval for type 2 diabetes, with plans to advance to phase II trials [2] - Huang Lian Jie Du Wan, as China's first "syndrome" type traditional Chinese medicine new drug, has completed phase II and III clinical trials over six years. The phase III trials evaluated its effectiveness, safety, and mechanism for treating traditional Chinese medicine's "excess heat and toxin syndrome." The project is now preparing for pre-market communication [2] Supply Chain and Market Strategy - Guizhou BaiLing has planted nearly 250,000 acres of medicinal herbs to ensure supply chain stability, implementing large-scale cultivation of over 20 varieties, including landmark herbs like Jixiang Grass and Tiger Ear Grass. The company has established a standardized control system to address the shortage of wild medicinal resources and ensure quality [3] - The market expansion strategy focuses on a "first in-hospital, then out-of-hospital" approach, targeting grassroots medical institutions, pharmacy chains, and private clinics. The "5+5" promotion plan aims to cover five quality clinics and five individual pharmacies, supported by professional talent recruitment and team motivation [3] Financial Status - The company reported a stable cash flow and a decrease in total bank loans, having optimized sales models and adjusted payment management processes to enhance cash flow [4] - Institutional investors expressed interest in Guizhou BaiLing's strategies in core product development, supply chain management, and market expansion, with the company committed to advancing its projects and optimizing its strategies for long-term growth [4]

Group 1: Company Performance and Market Conditions - The company's 2025 performance is influenced by two main factors: high proportion of four types of drugs (cold medicine, cough medicine, throat medicine, and antipyretics) and a market in destocking phase due to a decline in demand following a public health event in 2023 [3] - Weak consumer environment, including insufficient purchasing power, social inventory backlog, and adjustments in the medical insurance system, is impacting sales [3] Group 2: Research and Development Progress - The core research progress for the "Tang Ning Tong Luo" project includes the approval of its first indication for diabetic retinopathy, with 360 clinical patients being enrolled for phase III clinical trials [3] - The project has received a clinical trial approval notice for type 2 diabetes, with phase II clinical trials to follow [3] Group 3: Intellectual Property and Product Development - The company has implemented intellectual property protection measures for the "Tang Ning Tong Luo" project and is actively communicating with relevant departments to enhance protection [3] - "Huang Lian Jie Du Wan" is the first "syndrome-type" traditional Chinese medicine new drug in China, having completed phase III clinical trials with 840 cases enrolled [4] Group 4: Quality Control and Supply Chain Management - The company has planted over 25,000 acres of ecological medicinal herbs, covering various landmark medicinal materials to ensure quality and supply stability [4] - A core control standard has been established to address the shortage of wild medicinal resources and ensure quality through strict quality control systems [4] Group 5: Market Expansion and Financial Management - The company focuses on expanding its market by targeting grassroots medical institutions, chain pharmacies, and private clinics, employing a specialized promotion strategy [4] - Current cash flow is stable, with a reduction in total bank loans achieved through optimized sales models and improved payment management processes [4]

Group 1: Core Development Strategy - The core strategy revolves around four major platforms: scale manufacturing, industry chain integration, omnichannel sales, and large variety R&D [2][3] - The scale manufacturing platform aims to increase the company's herbal material processing capacity from 25,000 tons to 60,000 tons annually, supporting future sales growth [2][3] - The industry chain integration platform seeks to enhance product lines through licensing and branding strategies [2][3] Group 2: R&D Focus Areas - The company is focusing on the "Tian Ning Tong Luo" project for diabetes and its complications, which has over 10 years of clinical experience and is currently in Phase 3 clinical trials [3][4] - The "Huang Lian Jie Du Wan" project, a new type of traditional Chinese medicine, has completed Phase 2 and 3 clinical trials with 840 cases enrolled, targeting various diseases [4] Group 3: Sales and Marketing Optimization - High sales expense rates are attributed to a previous "big package" model, unclear product planning, and weak channel management [5] - The company is reforming its marketing system, transitioning from a big package model to a direct sales model, with 15 provinces already completed [5] - A market supervision department has been established to enhance oversight of business activities and financial management [5] Group 4: Financial Goals and Recovery Path - The revenue target for 2025 is projected at 4 billion CNY, with a net profit of 120 million CNY [6] - Recovery strategies include product price optimization, improving sales efficiency through direct sales reforms, and integrating advantageous products to enhance profitability [6] Group 5: Investment in Subsidiaries - Chengdu Zeling Biopharmaceutical Technology Co., Ltd. is a subsidiary in which the company holds a 17.6926% stake, focusing on innovative drug research and development [6]

Investment Rating - The report gives a "Buy" rating for the company, indicating an expected relative increase in stock price of over 20% compared to the benchmark index within six months [9][15]. Core Insights - The company has shown significant improvement in profitability and cost control, indicating a path towards high-quality development. In 2024, the operating revenue was 3.825 billion yuan, a decrease of 10.26%, while the net profit attributable to shareholders was 34 million yuan, an increase of 108.11% [3][4]. - The company has optimized its sales model through a direct sales reform pilot in nine provinces, which has led to steady growth in sales profits in those regions. By the end of 2024, the reform had been completed in six provinces, contributing positively to sales efficiency and profitability [5]. - The research pipeline is robust, with several new drug projects underway, including the Huanglian Jiedu Wan and Tang Ning Tong Luo projects. Successful approval and market entry of these projects could enhance the company's product structure and competitive edge [6]. Financial Performance Summary - For 2024, the gross margin was 58.09%, an increase of 2.80 percentage points, while the net profit margin was 0.88%, up by 10.60 percentage points. However, in Q1 2025, the gross margin dropped to 51.05%, a decrease of 12.79 percentage points [4]. - The company is projected to have revenues of 3.517 billion yuan in 2025, with net profits of 113 million yuan, reflecting a significant growth trajectory in subsequent years [9][11]. - The expected price-to-earnings (P/E) ratios for 2025, 2026, and 2027 are 66.5, 57.8, and 49.5 respectively, indicating a potential for valuation improvement as earnings grow [9][11].

Financial Status - The company currently has a sufficient cash flow, with management emphasizing the need for improved settlement and collection management [1] - Chairman Jiang Wei holds 245,346,284 shares, accounting for 17.55% of the total share capital, all of which are pledged [1] - Jiang Wei's total liabilities have significantly decreased, and his credit status is good, indicating a controllable pledge risk [1][2] R&D Progress - The "Sugar Ning Tong Luo" project has over 10 years of clinical use experience and has bypassed phases 1 and 2 of clinical trials, proceeding directly to phase 3 for diabetic retinopathy [3] - The "Huang Lian Jie Du Wan" project, China's first "general" syndrome-type traditional Chinese medicine new drug, has completed phase 2 and 3 clinical trials with 840 cases enrolled [4] - The project employs a unique "syndrome + biomarkers" evaluation method, aiming to provide a new treatment option for various diseases related to heat toxin syndrome [4] Product Pipeline - BD77, a potential first traditional Chinese medicine inhalant, has completed pilot production and safety evaluations [5][6] - "Yi Shen Hua Zhuo Granules" is in phase 2b clinical trials for primary membranous nephropathy [6] - "Ice Lotus Grass Tablets" have completed phase 3 clinical trials and are currently in data analysis [6] Supply Chain and Production Capacity - The company sources raw materials through a combination of external procurement and self-cultivation to mitigate price volatility risks [7] - The capacity for processing traditional Chinese medicine materials has increased from 25,000 tons per year to 60,000 tons per year [8] Strategic Partnerships - Chongqing Haifu has numerous patents and a strong market outlook due to its proprietary high-intensity focused ultrasound technology [9] - Yunnan Plant Pharmaceutical holds over 400 drug approvals, indicating significant future growth potential [10]

Group 1: Marketing Reform and Sales Performance - The company initiated a direct sales reform pilot in 9 provinces starting in 2022, achieving significant results with steady profit growth in these regions [1] - The direct sales reform has been completed in 15 provinces, covering major OTC markets, which is expected to enhance sales efficiency and profitability [1] - The marketing reform introduced new performance metrics such as per capita efficiency and store efficiency, moving away from solely focusing on growth rates [1] Group 2: Financial Indicators and Profitability - The company is experiencing positive feedback from its marketing reform, with good completion rates for sales and payment indicators [2] - The company aims to exceed previous net profit levels, supported by steady growth of existing products and new drug development projects [2] - The company plans to enhance its profit margin to meet or exceed the industry average, ensuring long-term stable development [2] Group 3: New Drug Development - The Huanglian Jiedu Wan is the first "general" syndrome-type traditional Chinese medicine new drug in China, with clinical trials involving 840 cases [3] - The project employs a unique evaluation method combining "syndrome types + biomarkers," which could set a precedent for the evaluation standards of syndrome-type traditional Chinese medicine [3] - If approved, Huanglian Jiedu Wan will provide new treatment options for numerous diseases related to heat toxin syndrome [3] Group 4: Investment in Subsidiaries - Chengdu Zeling Biopharmaceutical Technology Co., Ltd. is a subsidiary in which the company holds a 17.6926% stake, making it the second-largest shareholder [3] - The subsidiary focuses on innovative drug research and has completed multiple rounds of financing [3]

Group 1: Report General Information - The research object is Guizhou Bailing, belonging to the traditional Chinese medicine industry. The reception time was July 4, 2025, and the company's reception staff included the chairman, general manager, deputy general manager, financial director, and securities affairs representative [16] - The institutions participating in the research included Wang Lingyi, Pan Potao, Song Shijie, etc [2] Group 2: Company Business Analysis Marketing Reform - Since 2022, the company has launched a direct - sales system reform pilot in 9 provinces, and the reform has achieved remarkable results with steady growth in sales profits in reform areas. Currently, the direct - sales system reform has been completed in 15 provinces, which will positively impact the company's future sales efficiency and profitability [24] - The marketing model reform has changed the previous way of simply assessing growth rate, introducing assessment items such as per - capita efficiency and per - store efficiency, and reasonably formulating assessment indicators to mobilize the enthusiasm of sales staff. The company also plans to promote equity incentive plans in due course [24] - The company adheres to the profit - first orientation, optimizes the variety structure and price system, promotes the cultivation of large - scale varieties, and focuses on key national customers (NKA), regional large - scale chains (LKA), and the medical treatment sector to drive sales and profit growth [24] Sales Expense Optimization - The company's optimization of the sales expense ratio is a long - term task. It will continue to deepen the marketing system reform, gradually expand the coverage from the large - package model to the direct - sales model, and use the sales expense ratio in each region as a performance assessment indicator [24] - The company has established a market supervision department to vertically supervise the business activities and finances of branches and offices, and deeply participate in cost control and business negotiations [25] - Through optimizing and improving management, sales, and reward mechanisms, the company sets new assessment requirements for sales staff, strengthens budget assessment for direct - sales branches, and implements channel optimization policies for some varieties to reduce sales expenses. It also plans to promote equity incentive plans [25] Product R & D Progress - The Phase III clinical research of Tangning Tongluo is progressing normally according to the clinical protocol, and patients are being enrolled successively. The company will disclose information in a timely manner after achieving phased progress in R & D projects [26] Solvency - The company maintains long - term and stable cooperative relationships with multiple banks. After being removed from the risk warning list, the credit rating of the company by financial institutions will be upgraded. Considering factors such as the company's operating conditions, asset - liability structure, and asset utilization efficiency, the company does not have a solvency problem and will continue to optimize its asset - liability structure [26] Share Pledge - As of now, Chairman Jiang Wei holds 245,346,284 shares, accounting for 17.55% of the company's total shares, and 100% of his shares are pledged. The purpose of the share - pledged financing is for the investment and operation of non - listed company industries and the repayment of his stock - pledged repurchase transaction liabilities. The pledged shares do not bear performance compensation obligations [27] - Jiang Wei's total liabilities have been significantly reduced, and his credit status is good. The pledge risk is controllable, and there is currently no risk of forced liquidation. If such a risk occurs in the future, he will take measures such as early repurchase and additional pledges [27][28] R & D Expense Capitalization - The company manages R & D expenses in strict accordance with relevant accounting standards, and the annual report data has been audited by an accounting firm [29]

Core Viewpoint - Guizhou BaiLing is undergoing significant marketing reforms to enhance sales efficiency and profitability, with a focus on transitioning to a direct sales model across multiple provinces [2][3]. Group 1: Marketing Reform - The company initiated a direct sales reform pilot in nine provinces starting in 2022, which has led to steady profit growth in those regions [2]. - The reform has been implemented in a total of 15 provinces, aiming to improve sales efficiency and profitability [2]. - New performance metrics have been introduced, shifting from solely growth rate assessments to include per capita and per store efficiency, which motivates sales personnel [2]. Group 2: Sales Expense Management - The company is committed to optimizing its sales expense ratio through ongoing marketing system reforms and expanding coverage [2][3]. - A market supervision department has been established to oversee business activities and financial management across subsidiaries, enhancing cost control [3]. - The company is implementing new performance requirements for sales personnel and optimizing management and reward mechanisms to reduce sales expenses [3]. Group 3: Clinical Research Progress - The clinical research for Tangning Tongluo is progressing as planned, with patient enrollment ongoing [4]. Group 4: Financial Stability - The company maintains stable relationships with multiple banks, and its credit rating is expected to improve post-de-listing [5]. - The company does not face short-term solvency issues and is focused on optimizing its asset-liability structure [5]. Group 5: Shareholder Pledge - The chairman holds 17.55% of the company's shares, all of which are pledged for financing purposes unrelated to the company's operations [6]. - The chairman's debt has significantly decreased, and he has the capacity to repay, with no current risk of forced liquidation [6]. Group 6: R&D Expense Management - The company manages R&D expenses in accordance with accounting standards, with financial data audited by external firms [8]. - The company reported a significant decline in revenue and net profit in its Q1 2025 report, with total revenue of 761 million yuan, a 42.93% year-on-year decrease [8].

Group 1: Marketing Reform and Sales Efficiency - The company initiated a direct sales reform pilot in 9 provinces starting in 2022, achieving significant results with steady profit growth in these areas. The reform has now been completed in 15 provinces, positively impacting sales efficiency and profitability [1] - The marketing reform introduced new performance metrics such as per capita efficiency and store efficiency, moving away from solely focusing on growth rates. This aims to motivate sales personnel and align their income with company performance through potential stock incentive plans [1] - The company is focusing on optimizing product structure and pricing systems while nurturing major product lines and deepening relationships with key national customers [2] Group 2: Sales Expense Management - The company is continuously working on optimizing sales expense ratios through various strategies, including deepening marketing system reforms and transitioning from a large package model to a direct sales model [2] - A market supervision department has been established to oversee business activities and financial management across subsidiaries, enhancing expense control and commercial negotiations [2] - New performance requirements for sales personnel have been introduced, and budget assessments for direct subsidiaries are being strengthened to reduce sales expenses [2] Group 3: Clinical Research and Financial Stability - The clinical research for the product "Tangning Tongluo" is progressing as planned, with patient enrollment ongoing. The company will fulfill its information disclosure obligations upon achieving significant progress [2] - The company maintains stable long-term relationships with multiple banks, and its credit rating is expected to improve post-listing. There are no short-term solvency issues, and the company plans to continue optimizing its asset-liability structure [2] - The chairman holds 245,346,284 shares, representing 17.55% of the total share capital, all of which are pledged. The purpose of the pledge is for investment in non-listed companies and debt repayment, not for operational needs [3]

Group 1: Marketing Reform and Sales Strategy - The company is implementing a marketing model reform aimed at optimizing sales models, increasing profit contribution rates, and reducing sales expense ratios. Since 2022, the reform has been piloted in 9 provinces, resulting in steady sales profit growth in these regions. The reform has now been completed in 15 provinces, positively impacting future sales efficiency and profitability [1]. - The new marketing model shifts from solely assessing growth rates to incorporating metrics like per capita efficiency and store efficiency, motivating sales personnel. Future plans include introducing equity incentive programs to align employee benefits with company growth, transitioning personal income from property-based to asset-based income [1]. Group 2: Product Development and Clinical Trials - The Huanglian Jiedu Wan project, China's first "general" syndrome-type traditional Chinese medicine new drug, has completed Phase II and III clinical trials involving 840 cases. The trials focus on validating the drug's effectiveness and safety for treating specific Western medical diseases, providing a basis for future market approval [2]. - The company is progressing with the clinical research of Tang Ning Tong Luo, with patient enrollment ongoing. Updates will be disclosed as the project achieves milestones [2]. Group 3: Competitive Strategy and Market Positioning - The company has defined its new strategic positioning around four platforms: a large-scale manufacturing platform, an industry chain integration platform, an all-channel sales platform, and a large product R&D platform. The manufacturing capacity is expected to increase from 25,000 tons to 60,000 tons annually, enhancing future sales capabilities [3]. - The integration platform aims to strengthen product lines through licensing and branding strategies, while the all-channel sales platform focuses on comprehensive market coverage, including online and offline channels [3]. - The company aims to become a leader in the traditional Chinese medicine sector by leveraging its advantages in production capacity, sales, and R&D to effectively compete in the market [3]. Group 4: Financial Performance and Future Outlook - In Q1 2025, the company experienced a decline in performance due to last year's rapid growth and insufficient market demand. The company plans to focus on its core business and seek new growth points while enhancing its core capabilities and adapting to market changes [4]. - The company emphasizes improving operational quality, cash flow, profitability, and asset return rates through optimized management, sales models, and incentive mechanisms to achieve its annual business goals [4].